Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment.
about
The therapeutic profile of rolipram, PDE target and mechanism of action as a neuroprotectant following spinal cord injuryPhosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmiasSynthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's diseaseBrain-targeted proanthocyanidin metabolites for Alzheimer's disease treatmentReversal of long-term dendritic spine alterations in Alzheimer disease modelsThe Ubiquitin-Proteasome System: Potential Therapeutic Targets for Alzheimer's Disease and Spinal Cord InjuryPhosphodiesterase-5 Inhibitors: Action on the Signaling Pathways of Neuroinflammation, Neurodegeneration, and CognitionCombotherapy and current concepts as well as future strategies for the treatment of Alzheimer's diseaseBehavioral assays with mouse models of Alzheimer's disease: practical considerations and guidelines.PDE4 as a target for cognition enhancementEfficacy of selective PDE4D negative allosteric modulators in the object retrieval task in female cynomolgus monkeys (Macaca fascicularis)A loss of FUS/TLS function leads to impaired cellular proliferationDevelopment of Novel In Vivo Chemical Probes to Address CNS Protein Kinase Involvement in Synaptic DysfunctionSpines, plasticity, and cognition in Alzheimer's model miceDown-regulation of cAMP-dependent protein kinase by over-activated calpain in Alzheimer disease brainSynaptojanin 1-linked phosphoinositide dyshomeostasis and cognitive deficits in mouse models of Down's syndromePhosphodiesterases as therapeutic targets for Alzheimer's disease.A biphasic and brain-region selective down-regulation of cyclic adenosine monophosphate concentrations supports object recognition in the ratGEBR-7b, a novel PDE4D selective inhibitor that improves memory in rodents at non-emetic dosesSpecific Inhibition of Phosphodiesterase-4B Results in Anxiolysis and Facilitates Memory AcquisitionCdk5 is required for memory function and hippocampal plasticity via the cAMP signaling pathway.PDE4 inhibition enhances hippocampal synaptic plasticity in vivo and rescues MK801-induced impairment of long-term potentiation and object recognition memory in an animal model of psychosisCaenorhabditis elegans dnj-14, the orthologue of the DNAJC5 gene mutated in adult onset neuronal ceroid lipofuscinosis, provides a new platform for neuroprotective drug screening and identifies a SIR-2.1-independent action of resveratrol.Mitochondrial mislocalization underlies Abeta42-induced neuronal dysfunction in a Drosophila model of Alzheimer's disease.A large-scale chemical screen for regulators of the arginase 1 promoter identifies the soy isoflavone daidzeinas a clinically approved small molecule that can promote neuronal protection or regeneration via a cAMP-independent pathway.Memory-enhancing effects of GEBR-32a, a new PDE4D inhibitor holding promise for the treatment of Alzheimer's disease.(-)-Epigallocatechin-3-gallate ameliorates learning and memory deficits by adjusting the balance of TrkA/p75NTR signaling in APP/PS1 transgenic mice.Computational identification of potential multitarget treatments for ameliorating the adverse effects of amyloid-β on synaptic plasticityPhosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair.Phosphodiesterase type 4 inhibition does not restore ocular dominance plasticity in a ferret model of fetal alcohol spectrum disorders.Exercise improves cognition and hippocampal plasticity in APOE epsilon4 mice.Downregulation of CREB expression in Alzheimer's brain and in Aβ-treated rat hippocampal neurons.Brain region-specific decrease in the activity and expression of protein kinase A in the frontal cortex of regressive autism.Regulation of hippocampus-dependent memory by cyclic AMP-dependent protein kinasePharmacological and genetic reversal of age-dependent cognitive deficits attributable to decreased presenilin functionDesign and synthesis of neuroprotective methylthiazoles and modification as NO-chimeras for neurodegenerative therapy.New therapeutic approaches for Alzheimer's disease and cerebral amyloid angiopathy.Targeting multiple pathogenic mechanisms with polyphenols for the treatment of Alzheimer's disease-experimental approach and therapeutic implications.The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-β production and Tau hyperphosphorylation.A model of the roles of essential kinases in the induction and expression of late long-term potentiation.
P2860
Q21089854-02F6452B-86F8-4943-A790-18BE301661E7Q24337832-3F3304A1-487B-4169-BFFB-411AF97F1953Q24615907-6CC19B60-CF8E-496C-B8B4-37EF8C612289Q24624923-D723DA69-4E87-4151-9AEB-BCE1C51C0FB5Q24654995-FC97272B-D21C-4521-802A-40D6ACB9ABEBQ26767879-A08F9874-06C9-4391-8448-64D6D36C24BAQ26771954-1273803E-80A7-43A3-9DED-96B1B581F0E9Q26829899-E78116AC-A26A-48CA-84A1-32693D952610Q26858963-B8B1FF6F-1B10-4077-8F8D-C403855AE94CQ27008296-88F66E7E-9DB9-4E10-B8DA-1B517C4B5D98Q27319287-2B6141ED-9D38-4E98-8073-F29F5BA39C71Q27331026-3A7C3505-8F3F-4E07-836C-03C438D4956CQ27679012-82EFBBD0-AEFB-454E-98CD-5A0BE867AA72Q27691328-C6CD60E2-103C-4354-AE0C-08F0C2B05195Q27865198-C4D917AA-FA10-4C50-8CE8-92170CFC4E91Q28117514-57E2B24B-8BD2-4BF6-999B-43CFB2C8F5AEQ28279704-0A5B1901-CB37-4149-B89D-A47364DDAFB7Q28480922-9554F194-21DD-4D5D-9D29-AD04F6504E53Q28564847-A1C63B91-7009-4F02-A9A8-5A283A838391Q29028790-6BFAC277-E2D5-48F8-A00E-C42142CCBC01Q30430349-35000D38-0B6B-42D1-972E-FB1300BB630DQ30468797-0D16363B-7559-4AD4-9158-689F40F79909Q30594778-B7122362-EE7C-412A-965F-D1854A874E8DQ33519068-662B0BF7-FEDC-412B-A7E0-8FDE3641666DQ33523661-FEE92401-6BF1-48A7-998D-9DBE6DAD638BQ33556959-4CC3CC7C-CD71-4E2E-BD4B-CD771ECE94A4Q33574541-9BAFDF37-6137-4B99-A642-200BF2E46DFDQ33611723-14E5187C-F372-439F-9BA3-ED9BDB258D42Q33624262-A3886876-0DB3-486A-88B5-55F6875475D6Q33800535-FBDDD761-1E43-490B-B753-ADEE29E524C0Q33926265-055CF8A1-8E9E-4787-8DBA-90DEE99C8D5DQ33997810-5BEB8E3D-8B7D-413D-B631-C22C1EE28680Q34016340-39CB06ED-18C0-4CFE-8786-93CA63162E55Q34037728-4A6361BF-FAE7-47D7-9038-C84F389DE0EEQ34050670-F487EB42-EDDF-4AD1-99DA-5B4172158F50Q34332249-E3F2A4A2-2B9F-46BF-88BF-1894BDA04B9EQ34368970-32E70A40-C965-4038-9D51-F6363E054209Q34412322-E4F6E603-C329-42CC-885C-436FF5D961CAQ34444298-32835476-2A94-4407-B270-E29111EB6EF2Q34481520-FEEDE0D2-ECB1-4869-89F0-32243BC83CC6
P2860
Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2004
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Persistent improvement in syna ...... odel after rolipram treatment.
@en
Persistent improvement in syna ...... odel after rolipram treatment.
@nl
type
label
Persistent improvement in syna ...... odel after rolipram treatment.
@en
Persistent improvement in syna ...... odel after rolipram treatment.
@nl
prefLabel
Persistent improvement in syna ...... odel after rolipram treatment.
@en
Persistent improvement in syna ...... odel after rolipram treatment.
@nl
P2093
P2860
P356
P1476
Persistent improvement in syna ...... odel after rolipram treatment.
@en
P2093
Fabrizio Trinchese
Michael Shelanski
Ottavio V Vitolo
Shumin Liu
P2860
P304
P356
10.1172/JCI22831
P407
P577
2004-12-01T00:00:00Z